Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $3.2 million.

  • Editas Medicine's Accounts Payables fell 7467.78% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 7467.78%. This contributed to the annual value of $5.5 million for FY2024, which is 3357.12% down from last year.
  • Latest data reveals that Editas Medicine reported Accounts Payables of $3.2 million as of Q3 2025, which was down 7467.78% from $6.7 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Accounts Payables ranged from a high of $13.8 million in Q2 2024 and a low of $3.2 million during Q3 2025
  • Over the past 5 years, Editas Medicine's median Accounts Payables value was $6.8 million (recorded in 2022), while the average stood at $7.4 million.
  • Per our database at Business Quant, Editas Medicine's Accounts Payables surged by 10094.06% in 2022 and then crashed by 7467.78% in 2025.
  • Quarter analysis of 5 years shows Editas Medicine's Accounts Payables stood at $5.0 million in 2021, then soared by 88.34% to $9.5 million in 2022, then decreased by 13.06% to $8.3 million in 2023, then plummeted by 33.57% to $5.5 million in 2024, then plummeted by 42.42% to $3.2 million in 2025.
  • Its Accounts Payables stands at $3.2 million for Q3 2025, versus $6.7 million for Q2 2025 and $5.5 million for Q1 2025.